Trial Profile

A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 3745417 (Primary) ; Pembrolizumab (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors GlaxoSmithKline

Most Recent Events

21 May 2024 Planned End Date changed from 5 Apr 2024 to 31 Mar 2025.
21 May 2024 Planned primary completion date changed from 5 Apr 2024 to 31 Mar 2025.
08 Feb 2024 Planned End Date changed from 17 Aug 2024 to 5 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com